Ali Wakil

Dr. Ali Wakil

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2022 in Journal of Clinical and Experimental Hepatology
Verified
Journal Article
Closed access
AWAli Wakil
Ali Wakil
MNMumtaz Niazi
Mumtaz Niazi
MMMohamad Meybodi
Mohamad Meybodi
NPNikolaos T. Pyrsopoulos
Nikolaos T. Pyrsopoulos

12 December 2022 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
AWAli Wakil
Ali Wakil
YWYi-Chia Wu
Yi-Chia Wu
NMNatale Mazzaferro
Natale Mazzaferro
PGPatricia Greenberg
Patricia Greenberg
NPNikolaos T. MD Pyrsopoulos
Nikolaos T. MD Pyrsopoulos
Introduction: Liver cancer, including Hepatocellular carcinoma (HCC) is the seventh most common tumor worldwide. Previously, the financial burden of HCC in the United States between 2002 and 2011 was noted to be continuously increasing. This study aims to evaluate temporal trends of hospitalizations due to HCC. Method: This is a retrospective analysis utilizing the National Inpatient Sample (NIS) database. All subjects admitted between 2011 and 2017 with a diagnosis of HCC were identified. The primary trend characteristics were in-hospital mortality, hospital charges, and length of stay. Results: An increase in hospitalization from 67,779 (0.18%) admissions in 2011 to 84,580 (0.23%) admissions in 2017(P<0.05) was noted. Most patients were 45 to 64 years old (median 50%), predominantly men (median 68%) (P<0.05). The primary health care payer was Medicare (Median 49%) and Medicaid (Median 18%) (P<0.05). The most common geographical location was the south (Median 36%) (P<0.05). Most patients were admitted to large hospitals (Median 62%) in urban areas (P<0.05). The median inpatient mortality was estimated to be 9% in 2017 (P<0.05), which has decreased from 10%(P<0.05) in 2011. The total charges per admission have increased steadily from $58,406 in 2011 to $78,791 in 2017 (P<0.05). The median length of stay has increased from 5.79 (SD 6.93) in 2011 to 6.07 (SD 8.3) in 2017(P<0.05). The most common mortality risk factor was sepsis, Acute renal failure, and GI hemorrhage. Conclusion: HCC-related admissions continue to be on the rise. HCC mortality has decreased across the years with earlier diagnoses and advances in therapy. However, we observed a significant increase in financial burden on health care with increasing in-hospital costs, a finding that needs to be verified in prospective trials.

27 April 2023 in Clinics in Liver Disease
Verified
Journal Article
Closed access
AWAli Wakil
Ali Wakil
MNMumtaz Niazi
Mumtaz Niazi
KLKeri E. Lunsford
Keri E. Lunsford
NPNikolaos Pyrsopoulos
Nikolaos Pyrsopoulos

28 August 2025 in Gastroenterology Insights
Verified
Journal Article
Open access
PDF file
MGManasa Ginjupalli
Manasa Ginjupalli
PBPraneeth Kumar Reddy Bandaru
Praneeth Kumar Reddy Bandaru
ASAnuj Raj Sharma
Anuj Raj Sharma
JJJayalekshmi Jayakumar
Jayalekshmi Jayakumar
RFRaissa Nana Sede Mbakop Forlemu
Raissa Nana Sede Mbakop Forlemu
MRMadhavi Reddy
Madhavi Reddy
Background: Hepatocellular carcinoma (HCC) is a major global health burden and a leading cause of cancer-related deaths. While aspirin has shown potential chemopreventive effects in chronic liver disease, its impact on clinical outcomes among patients hospitalized with HCC remains under-investigated. Methods: Using the National Inpatient Sample (NIS) from 2016 to 2022, we conducted a retrospective cohort study to evaluate the association between aspirin use and clinical outcomes in adult HCC hospitalizations. Patients were stratified based on documented aspirin use, and propensity score matching with inverse probability of treatment weighting (IPTW) was applied to minimize confounding. The primary outcome was in-hospital mortality; secondary outcomes included morbidity-related complications, hospital length of stay, and total charges. Results: Among 337,730 hospitalizations with HCC, 8.37% involved aspirin use. Aspirin users demonstrated significantly lower in-hospital mortality (5.2% vs. 10.09%), with an adjusted odds ratio (OR) of 0.58 (95% CI: 0.50–0.68; p < 0.001). Aspirin use was also associated with shorter hospital stays (5.42 vs. 6.39 days), lower total charges ($80,310 vs. $95,098), and reduced incidence of complications, including acute liver failure, hepatic encephalopathy, ascites, spontaneous bacterial peritonitis, sepsis, ICU admission, and acute kidney injury. Importantly, no statistically significant increase in gastrointestinal or variceal bleeding was observed among aspirin users. Conclusions: These findings suggest that aspirin use may reduce mortality, morbidity, and healthcare burden in patients hospitalized with HCC.

6 March 2026 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
ZZZohyra E. Zabala
Zohyra E. Zabala
TDTaranika Sarkar Das
Taranika Sarkar Das
WGWendy Garzon
Wendy Garzon
AWAli Wakil
Ali Wakil
CNChanakya Nayudu
Chanakya Nayudu
SVSushma Venugopal
Sushma Venugopal
An abstract is unavailable. This article is available as a PDF only.

2 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MGManasa Ginjupalli
Manasa Ginjupalli
PBPraneeth Bandaru
Praneeth Bandaru
ASAnuj Raj Sharma
Anuj Raj Sharma
JJJayalekshmi Jayakumar
Jayalekshmi Jayakumar
RFRaissa Nana Sede Mbakop Forlemu
Raissa Nana Sede Mbakop Forlemu
MRMadhavi Reddy
Madhavi Reddy
Background Hepatocellular carcinoma (HCC) is a major global health burden and a leading cause of cancer-related deaths. While aspirin has shown potential chemo preventive effects in chronic liver disease, its impact on clinical outcomes among patients hospitalized with HCC remains under-investigated. Methods Using the National Inpatient Sample (NIS) from 2016 to 2022, we conducted a retrospec-tive cohort study to evaluate the association between aspirin use and clinical outcomes in adult HCC hospitalizations. Patients were stratified based on documented aspirin use, and propensity score matching with inverse probability of treatment weighting (IPTW) was applied to minimize confounding. The primary outcome was in-hospital mortality; secondary outcomes included morbidity-related complications, hospital length of stay, and total charges. Results Among 337,730 hospitalizations with HCC, 8.37% involved aspirin use. Aspirin users demonstrated significantly lower in-hospital mortality (5.2% vs. 10.09%), with an adjusted odds ratio (OR) of 0.58 (95% CI: 0.50–0.68; p < 0.001). Aspirin use was also associated with shorter hospital stays (5.42 vs. 6.39 days), lower total charges ($80,310 vs. $95,098), and reduced incidence of complications including acute liver failure, hepatic encephalopathy, ascites, spontaneous bacterial peritonitis, sepsis, ICU admission, and acute kidney injury. Importantly, no statistically significant increase in gastrointestinal or variceal bleeding was observed among aspirin users. Conclusion These findings suggest that aspirin use may reduce mortality, morbidity, and healthcare burden in patients hospitalized with HCC.